Eleva completed the single-ascending dose portion of its first-in-human study of CPV-104, a recombinant human Factor H, in 21 healthy volunteers across four dose cohorts with no safety concerns, and is moving immediately into a multiple-ascending dose phase in 18 patients with biopsy-confirmed C3 glomerulopathy over four weeks. The trial is assessing safety, tolerability, and pharmacokinetics, with pharmacodynamic readouts expected to include complement pathway biomarkers relevant to C3G.
The core development is the transition from healthy volunteer testing to patient dosing of the only Factor H replacement therapy in clinical development, supported by EU Orphan Drug Designation. CPV-104 is manufactured using Eleva’s moss-based GMP platform, positioned to solve a longstanding manufacturability barrier for Factor H. This large, heavily glycosylated complement regulator has resisted scale-up in CHO and yeast systems. The multiple-ascending dose phase will run three cohorts further to characterize safety and dose-dependent activity in the target population.
Strategically, Eleva is advancing a class-of-one approach in a crowded landscape by inhibitors targeting C3, C5, factor B, and factor D. Rather than blocking downstream effectors, Factor H replacement aims to restore physiologic control of the alternative pathway at its origin, a potentially cleaner mechanism in patient subsets where dysregulation is driven by Factor H deficiency or dysfunction. The bet is twofold: that manufacturability—historically the gating factor—has been de-risked by the moss platform, and that regulators will accept biomarker-driven signals as a bridge to slower renal outcomes in an ultra-rare, heterogeneous disease. The tension is apparent. Immunogenicity risk for a large recombinant protein with complex glycosylation must be proven manageable in patients, and a four-week dosing window is short to show meaningful renal benefit, making robust PD shifts in serum C3, AH50, and sC5b-9 essential to maintain momentum.
For sites and CROs, the move into C3G patients adds operational complexity typical of complement nephrology studies: centralized complement assays, standardized biopsy criteria, and careful management of concomitant immunosuppression. With only 18 patients across three cohorts, this is likely a tightly networked, biomarker-heavy study at a limited number of experienced nephrology centers, favoring sponsors and vendors with complement-specific assay capabilities and cold-chain reliability for a biologic with unique manufacturing provenance. For sponsors tracking the category, Factor H therapy—if feasible at scale—could reshape trial design away from broad complement blockade and toward etiologic correction, potentially with different safety surveillance obligations. Regulators will watch how PD shifts correlate with early renal markers and whether the platform’s glycosylation profile mitigates anti-drug antibody formation.
Next, the key readouts to watch are dose-dependent changes in alternative pathway activity, normalization of serum C3, early signals on proteinuria, and the incidence and titers of anti-drug antibodies. Clarity on route and frequency of administration will matter for chronic viability in a renal population. If mechanistic signals are strong, Eleva will need to lock in alignment with EMA and FDA on surrogate endpoints suitable for a pivotal study in C3G. In this setting, traditional eGFR-based endpoints can be impractical. On the CMC front, consistency of moss-based glycosylation and comparability through scale-up will be as determinative as clinical data for regulatory progression. A positive Phase 1b could also catalyze partnerships for late-stage development and manufacturing. The open questions are whether Factor H replacement can deliver durable disease modification in a heterogeneous rare population and whether the platform can sustain the quality and volume required for a chronic renal indication.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
